Tech entrepreneur, futurist and philanthropist Jason Hope believes in the long-term promise of longevity science.
Hope was one of the earliest backers of the non-profit Strategies for Engineered Negligible Senescence (SENS) Research Foundation. His half million dollar pledge led to the creation of a laboratory at the University of Cambridge in 2010. The SENS Foundation focuses on healing the damaged cells and tissues that lead to disease through the aging process. These diseases include heart disease, diabetes and Alzheimer’s.
Hope has stated, “We must look past treating the symptoms of aging and start considering preventing those problems in the first place.”
Like Jason Hope on Facebook.
Research is only the first step. Science needs supporters to move from research to application. Jason Hope has been a persuasive proponent of the foundation and of rejuvenation science. In 2013, he helped raise money by matching the donations raised by the Fight Aging! campaign. His involvement has generated interest among the most influential people in technology and business. Investment in biotechnology companies relevant to rejuvenation therapies has increased.
In 2016, SENS research moved closer to reality. With the support of generous philanthropists like Jason Hope, Michael Greve and Peter Thiel, several science startups have begun clinical development on biotech projects and related therapies. Gensight is working toward a gene-based treatment to cure hereditary mitochondrial disease. Ichor Therapeutics is continuing SENS’ original research into retinal aging. Hope himself is involved in Human Rejuvenation Technologies. His company is developing a drug-based treatment for eliminating metabolic waste that contributes to atherosclerosis.
As longevity science moves into the tangible world of biotechnology, two things are clear. The collaboration of science, entrepreneurship and philanthropy is an effective strategy to solve the puzzle of aging and disease. It’s a solution that Jason Hope will be a part of for many years to come.